IMMUNEERING CORP - CLASS A (IMRX)
US45254E1073 - Common Stock
Taking everything into account, IMRX scores 2 out of 10 in our fundamental rating. IMRX was compared to 565 industry peers in the Biotechnology industry. While IMRX has a great health rating, there are worries on its profitability. IMRX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year IMRX has reported negative net income.
In the past year IMRX has reported a negative cash flow from operations.
In the past 5 years IMRX always reported negative net income.
IMRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -52.13%, IMRX perfoms like the industry average, outperforming 46.62% of the companies in the same industry.
The Return On Equity of IMRX (-59.04%) is better than 61.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.13% | ||
| ROE | -59.04% | ||
| ROIC | N/A |
ROA(3y)-37.84%
ROA(5y)-42.51%
ROE(3y)-42.16%
ROE(5y)-50.14%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMRX has more shares outstanding
IMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IMRX has an Altman-Z score of 0.26. This is a bad value and indicates that IMRX is not financially healthy and even has some risk of bankruptcy.
IMRX's Altman-Z score of 0.26 is fine compared to the rest of the industry. IMRX outperforms 64.95% of its industry peers.
There is no outstanding debt for IMRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.26 |
ROIC/WACCN/A
WACC10.91%
2.3 Liquidity
IMRX has a Current Ratio of 11.35. This indicates that IMRX is financially healthy and has no problem in meeting its short term obligations.
IMRX has a better Current ratio (11.35) than 84.52% of its industry peers.
IMRX has a Quick Ratio of 11.35. This indicates that IMRX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 11.35, IMRX belongs to the best of the industry, outperforming 84.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.35 | ||
| Quick Ratio | 11.35 |
3. Growth
3.1 Past
The earnings per share for IMRX have decreased by -5.35% in the last year.
IMRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-5.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.95%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, IMRX will show a small growth in Earnings Per Share. The EPS will grow by 5.71% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.03%
EPS Next 2Y4.68%
EPS Next 3Y-3.35%
EPS Next 5Y5.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IMRX. In the last year negative earnings were reported.
Also next year IMRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as IMRX's earnings are expected to decrease with -3.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.68%
EPS Next 3Y-3.35%
5. Dividend
5.1 Amount
IMRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IMMUNEERING CORP - CLASS A
NASDAQ:IMRX (12/23/2024, 8:12:17 PM)
Premarket: 2.19 -0.01 (-0.45%)2.2
+0.2 (+10%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners32.46%
Inst Owner Change-54.33%
Ins Owners19.84%
Ins Owner Change0.11%
Market Cap68.31M
Analysts80
Price Target11.44 (420%)
Short Float %7.22%
Short Ratio1.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.77%
Min EPS beat(2)-9.09%
Max EPS beat(2)14.62%
EPS beat(4)3
Avg EPS beat(4)9.08%
Min EPS beat(4)-9.09%
Max EPS beat(4)20.08%
EPS beat(8)6
Avg EPS beat(8)7.92%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)-0.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.75 | ||
| P/tB | 0.82 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.97
EYN/A
EPS(NY)-1.71
Fwd EYN/A
FCF(TTM)-1.59
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS0
BVpS2.92
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.13% | ||
| ROE | -59.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-37.84%
ROA(5y)-42.51%
ROE(3y)-42.16%
ROE(5y)-50.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 97.35% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.35 | ||
| Quick Ratio | 11.35 | ||
| Altman-Z | 0.26 |
F-Score2
WACC10.91%
ROIC/WACCN/A
Cap/Depr(3y)160.54%
Cap/Depr(5y)166.33%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.95%
EPS Next Y-2.03%
EPS Next 2Y4.68%
EPS Next 3Y-3.35%
EPS Next 5Y5.71%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.25%
EBIT Next 3Y-14.48%
EBIT Next 5Y-19.96%
FCF growth 1Y-9.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.04%
OCF growth 3YN/A
OCF growth 5YN/A